Medical Cannabis for Fibromyalgia UK

Evidence Note: Evidence strength varies by condition. Chronic pain and epilepsy have the strongest clinical evidence base. Other conditions are treated based on specialist clinical judgement and emerging research. All prescriptions require specialist assessment.

Understanding Fibromyalgia

Fibromyalgia is a chronic, complex pain disorder characterised by widespread musculoskeletal pain, fatigue, sleep dysfunction, and cognitive impairment. It affects an estimated 2-4% of the UK population, with a 4:1 female-to-male ratio. The underlying pathophysiology involves central sensitisation — a state of amplified pain processing in which the central nervous system becomes hyper-responsive to sensory inputs. Current pharmacological recommendations focus on centrally-acting agents: pregabalin, duloxetine, and amitriptyline — but only a minority of patients achieve adequate relief, and these medications carry significant side effects.

The Endocannabinoid Deficiency Hypothesis

Rheumatologist Dr Ethan Russo proposed the Clinical Endocannabinoid Deficiency (CECD) hypothesis in 2003, arguing that fibromyalgia may share a common pathophysiology rooted in insufficient endocannabinoid tone. Fibromyalgia patients have significantly lower levels of the endogenous cannabinoid anandamide in cerebrospinal fluid compared to healthy controls, and there are documented alterations in CB1 receptor expression in the spinal cord of fibromyalgia patients.

Clinical Evidence

A 2019 observational study in PLOS One (Sagy et al.) involving 367 fibromyalgia patients found 81% reported being much improved or very much improved after six months. Pain intensity decreased from a median of 9.0 to 5.0 on a 10-point scale.
A retrospective analysis of the UK Medical Cannabis Registry (2022) found statistically significant improvements in pain severity, sleep quality, and health-related quality of life at one, three, and six months.

Symptom Response

Most responsive: Sleep dysfunction (often the first and most dramatic improvement), widespread pain intensity, restless legs
Moderately responsive: Fatigue, mood disturbance, headache frequency
Variable: Cognitive function — some patients report improvement, others require dosing adjustment

Product Selection

Given the importance of sleep restoration in fibromyalgia, specialists often favour products with both THC and CBD content. A common approach is a low-dose THC:CBD oil taken in the evening for sleep and pain, with a CBD-dominant formulation used during the day. All products available through Cannamedical Britannia meet EU-GMP manufacturing standards with full batch testing.

Frequently Asked Questions

Can medical cannabis help fibromyalgia?

Growing clinical evidence from observational registries in Israel, Germany, and the UK suggests that medical cannabis can provide meaningful reductions in pain intensity, sleep disturbance, and fatigue in fibromyalgia patients.

Is fibromyalgia recognised for medical cannabis prescribing in the UK?

Yes. The UK regulations permit prescribing based on clinical judgment rather than a fixed conditions list. Specialist doctors regularly prescribe cannabis-based medicines for fibromyalgia where conventional treatments have failed.

Why does fibromyalgia respond to cannabinoids?

Fibromyalgia is characterised by central sensitisation and dysfunction of the endocannabinoid system. Research suggests fibromyalgia patients have reduced levels of endogenous cannabinoids and altered CB receptor expression. Exogenous cannabinoids may help correct this deficit.

What does the evidence say about cannabis and fibromyalgia?

A large Israeli registry study (Sagy et al., 2019, PLOS One) involving 367 fibromyalgia patients found 81% reported much improved or very much improved overall after six months. Pain intensity decreased from a median of 9.0 to 5.0.